In Re Exaeris, Inc.

380 B.R. 741, 2008 Bankr. LEXIS 63, 49 Bankr. Ct. Dec. (CRR) 91, 2008 WL 141500
CourtUnited States Bankruptcy Court, D. Delaware
DecidedJanuary 15, 2008
Docket17-12681
StatusPublished
Cited by6 cases

This text of 380 B.R. 741 (In Re Exaeris, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Exaeris, Inc., 380 B.R. 741, 2008 Bankr. LEXIS 63, 49 Bankr. Ct. Dec. (CRR) 91, 2008 WL 141500 (Del. 2008).

Opinion

MEMORANDUM OPINION 1

KEVIN GROSS, Bankruptcy Judge.

INTRODUCTION

The Debtor, Exaeris, Inc. (“Exaeris” or “Debtor”) has filed an expedited motion seeking an order authorizing the sale of substantially all of the assets of Exaeris to Dr. Jack Kachkar (“J. Kachkar”) or his designee (“the Sale”), the assumption of designated executory contracts and unexpired leases and the settlement of certain claims between J. Kachkar and Exaeris (“the Motion”). D.I. 406. The Court conducted an evidentiary hearing on the Motion on January 11, 2008 (“the Hearing”). The Official Committee of Unsecured Creditors (“the Committee”) took the lead in presenting the Motion, with Debtor’s support. The Motion is opposed by West-ernbank Puerto Rico (“Westernbank”), a creditor. This is the Court’s decision on the Motion which, because of the time limitation explained below, is by necessity brief and to the point.

THE CASE

Debtor initiated its Chapter 11 case in this Court on July 2, 2007, together with Inyx USA, Ltd. (“Inyx USA”). Exaeris and Inyx USA are both wholly owned subsidiaries of Inyx, Inc. (“Inyx”), which is a specialty pharmaceutical company and provides manufacturing and development services of both prescription and over-the-counter products. Exaeris, with its principal place of business in Exton, Pennsylvania, is involved in marketing and promotional activities for Inyx and other companies. The Exaeris and Inyx USA *743 cases were jointly administered at the outset of their cases. On August 8, 2007, the Court appointed a Chapter 11 Trustee for Inyx USA with the agreement of parties in interest. On December 6, 2007, on the motion of Westernbank, the Court entered an Order directing that the Exaeris and Inyx USA cases would no longer be jointly administered. D.I. 421.

J. Kachkar provided Exaeris with post petition financing in an amount up to $2.1 million, with interest at the rate of 9.5% per annum on funds actually advanced. The Court entered interim and final orders authorizing J. Kachkar’s financing. D.I.’s 43,122,168,195 and 241.

Exaeris is presently not operating, having laid off its employees and discontinued all of its operations except for the eye care business which its wholly owned subsidiary, Exaeris Holdings, Ltd., operates. The Committee, with Debtor’s approval, began negotiations with J. Kachkar for the sale of Exaeris to J. Kachkar which resulted in the Asset Purchase Agreement, dated December 17, 2007, between J. Kachkar and Exaeris (“the APA”) which is presently before the Court. The essential terms of the APA are as follows:

Purchase Price: Credit bid of the financing J. Kachkar provided (approximately $2.1 million) and a cash payment of $337,500.
Purchased Assets: The Exaeris business, causes of action against King Pharmaceuticals and Dava Pharmaceuticals, claims against Inyx, claims against J. Kachkar, the stock of Ex-aeris Holdings, Ltd., all cash deposits, all books and records, good will, trademarks, licenses, copyrights and the like, machinery and equipment, inventory, customer lists, trade accounts, and other business operations materials and information.
Retained Assets: Debtor will retain Bankruptcy Code Chapter 5 causes of action, state-law fraudulent transfer actions, setoff against Dava Pharmaceuticals, interests in contracts with King, Dava and Ventiv, the lease for the offices.
Assumed Liabilities: J. Kachkar will assume unpaid administrative expenses and the fees and expenses of the Committee’s professionals up to $62,500.

RELEVANT FACTS

There are a limited universe of relevant, but critical, facts to the Court’s decision and in the short time the Court has to issue its decision, it is both necessary and helpful to bring them to the forefront.

1. J. Kachkar was both an insider of Exaeris at the commencement of the case 2 and the lender of debtor-in-possession financing.

2. Exaeris is not an operating business and its estate appears to be administratively insolvent. However, in the year before its bankruptcy, Exaeris generated over $5 million in revenues and has accounts receivable in excess of $2.5 million.

3. Assuming Debtor’s suggestion is correct that the entire cash payment under the APA went to pay claims, and assuming that the claims totaled $5 million — a best case scenario in the extreme — the sale would generate approximately $.06 per *744 dollar of claim. The assumptions mean that none of the cash would be used for professional fees or other administrative expenses and that the amount of claims are less than the Court anticipates. One creditor alone has a claim of approximately $6 million. It is more likely that the Sale will not generate any recovery for creditors.

4. The “emergency” of the Motion is premised on J. Kachkar’s insistence upon a closing deadline less than one month from the APA.

5. The Committee’s financial advisor testified at the Hearing and was unable to provide any valuation of the assets J. Kachkar would purchase under the APA. Neither the Committee nor the Debtor were able to provide the Court with the value of the Exaeris business.

6. The Committee’s financial advisor was responsible for the marketing of Ex-aeris in order to attract other interested buyers at an auction. The efforts did not result in any interested purchasers and, more troubling, at the Hearing the financial advisor was unable to name a single person or entity with whom he communicated.

7. The Committee’s conclusion that the release of J. Kachkar is fair and reasonable is premised upon an investigation which was not described to the Court and was conducted without discovery, with access to a very small universe of documents, and in the very short and insufficient time dictated by J. Kachkar.

DISCUSSION

At issue is Debtor’s sale of all or substantially all of its assets, outside of a plan of reorganization. Such relief is not unusual or inappropriate, but requires a bankruptcy court’s careful review. The sale of assets which is not in the debtor’s ordinary course of business requires proof that: (1) there is a sound business purpose for the sale; (2) the proposed sale price is fair; (3) the debtor has provided adequate and reasonable notice; and (4) the buyer has acted in good faith. In re Delaware & Hudson Railway Co., 124 B.R. 169, 176 (D.Del.1991). The element of “good faith” is of particular importance, as the Third Circuit made clear in In re Abbotts Dairies of Pennsylvania, Inc., 788 F.2d 143, 149-50 (3d Cir.1986) (“... when a bankruptcy court authorizes a sale of assets pursuant to section 363(b)(1), it is required to make a finding with respect to the ‘good faith’ of the purchaser.”).

The Debtor and the Committee failed to establish at the Hearing that the Sale satisfies any of the foregoing requirements. The timing, relationship of J. Kachkar to Exaeris, the proposed release of J.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Flour City Bagels, LLC
557 B.R. 53 (W.D. New York, 2016)
In re Family Christian, LLC
533 B.R. 600 (W.D. Michigan, 2015)
In re Buerge
479 B.R. 101 (D. Kansas, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
380 B.R. 741, 2008 Bankr. LEXIS 63, 49 Bankr. Ct. Dec. (CRR) 91, 2008 WL 141500, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-exaeris-inc-deb-2008.